ADMA
ADMA BIOLOGICS, INC.
$8.06
+1.13%
$1.9B
No data for this timeframe.
Vol
Market Cap$1.9B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (80%)
Inst. Holders9 funds
Inst. Value$542.4M
Inst. Activity2 buys / 3 sells
Insider Activity5B / 3S
Insider Net $-$158.1K
Reddit Sentiment40° Cool
SEC Reports3
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001368514·Prev Close $7.97
Recent Activity
May 27, 2026
Insider
Grossman Jerrold B bought 6,400 shares
Director @ $7.91 ($50.6K)
May 12, 2026
Insider
Grossman Jerrold B bought 12,500 shares
Director @ $8.01 ($100.1K)
May 11, 2026
Insider
Grossman Jerrold B bought 12,500 shares
Director @ $8.01 ($100.1K)
May 6, 2026
earnings_calendar
ADMA Q1 2026 Earnings Scheduled — 2026-05-06
May 4, 2026
SEC
ADMA Biologics received FDA approval for label expansion of ASCENIV to include pediatric immune compromised patients age
8-K — Impact 6/10
Apr 15, 2026
SEC
Analysis based on filing metadata only — document content was unavailable
DEFA14A — Impact 2/10
Feb 25, 2026
SEC
ADMA Biologics reported record financial results for 2025 with 20% YoY revenue growth to $510 million and 35% growth in
8-K — Impact 8/10
Inst.
MORGAN STANLEY — ADD
1,948,373 shares ($35.5M)
Price Targets
$16.75
+106.3% upside
Strong Buy
Current $8.12
Low $12.00
Median $17.50
High $20.00
4 analysts
$12.00
$20.00
Analyst Ratings
2Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 7, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| May 7, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| Apr 21, 2026 | Canaccord Genuity | INITIATE | Buy |
| Apr 13, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| Mar 26, 2026 | Cantor Fitzgerald | DOWNGRADE | Overweight → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.18 ▼ -28.0% | $0.18 — $0.18 | 24% YoY | 2 |
| Next Q | $0.21 ▼ -25.0% | $0.21 — $0.21 | 32% YoY | 2 |
| Current FY | $0.83 ▼ -13.1% | $0.83 — $0.83 | 26% YoY | 1 |
| Next FY | $1.06 ▼ -14.8% | $1.02 — $1.10 | 27% YoY | 3 |
Latest Reports
BULLISH
8-K
6/10
ADMA Biologics received FDA approval for label expansion of ASCENIV to include pediatric immune compromised patients age
May 4, 2026
NEUTRAL
DEFA14A
2/10
Analysis based on filing metadata only — document content was unavailable
Apr 15, 2026
MIXED
Press
6/10
ADMA Biologics issued a press release refuting allegations from a short seller report that accused the company of channe
Mar 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $380.4M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $41.2M | NEW |
| MORGAN STANLEY | $35.5M | ADD |
| BANK OF AMERICA CORP | $35.1M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $28.0M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 27, 2026 | Grossman Jerrold | BUY | $50.6K |
| May 12, 2026 | Grossman Jerrold | BUY | $100.1K |
| May 11, 2026 | Grossman Jerrold | BUY | $100.1K |
| Apr 1, 2026 | Kestenberg-Messina Kaitlin | F | $185.5K |
| Mar 17, 2026 | Guiheen Lawrence | G | $0.00 |
Reddit Sentiment
40°▲
Cool
Bearish
Neutral
Bullish
9 institutional holders with $542.4M total value (29,989,458 shares) as of 2025-Q4. Top holders: VANGUARD, CHARLES, MORGAN. Net selling activity: 3 institutions trimmed/exited vs 2 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 20,854,669 | $380.4M | 70.1% | ADD +26.9% |
| 2 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,257,708 | $41.2M | 7.6% | NEW |
| 3 | MORGAN STANLEY | 1,948,373 | $35.5M | 6.6% | ADD +33.6% |
| 4 | BANK OF AMERICA CORP /DE/ | 1,926,337 | $35.1M | 6.5% | ADD +67.9% |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 1,532,621 | $28.0M | 5.2% | TRIM -44.7% |
| 6 | TWO SIGMA INVESTMENTS, LP | 504,174 | $9.2M | 1.7% | TRIM -43.9% |
| 7 | WELLS FARGO & COMPANY/MN | 411,132 | $7.5M | 1.4% | TRIM -61.3% |
| 8 | FMR LLC | 302,244 | $5.5M | 1.0% | TRIM -58.7% |
| 9 | Duquesne Family Office LLC | 252,200 | $4.6K | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 1,458,194 | 1,948,373 | +33.6% | $35.5M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 1,147,376 | 1,926,337 | +67.9% | $35.1M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 2,770,442 | 1,532,621 | -44.7% | $28.0M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 898,028 | 504,174 | -43.9% | $9.2M | 2025-Q4 |
| FMR LLC | TRIM | 732,662 | 302,244 | -58.7% | $5.5M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 1,961,585 | 1,458,194 | -25.7% | $21.4M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 1,202,101 | 898,028 | -25.3% | $13.2M | 2025-Q3 |
| FMR LLC | NEAR_EXIT | 3,212,574 | 732,662 | -77.2% | $10.7M | 2025-Q3 |
| NORGES BANK | EXIT | 30,133 | 0 | -100.0% | $0.00 | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 16,841,449 | 21,363,715 | +26.9% | $389.0M | 2025-Q2 |
| MORGAN STANLEY | TRIM | 4,913,928 | 1,961,585 | -60.1% | $35.7M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 701,775 | 1,231,639 | +75.5% | $22.4M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 2,255,306 | 1,202,101 | -46.7% | $21.9M | 2025-Q2 |
| NORGES BANK | NEW | — | 30,133 | — | $548.7K | 2025-Q2 |
| UBS Group AG | DOUBLED | 1,003,932 | 2,816,814 | +180.6% | $55.9M | 2025-Q1 |
| NORGES BANK | EXIT | 119,344 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | TRIM | 8,599,618 | 5,534,337 | -35.6% | $94.9M | 2024-Q4 |
| UBS Group AG | DOUBLED | 417,705 | 1,003,932 | +140.3% | $17.2M | 2024-Q4 |
| CITADEL ADVISORS LLC | ADD | 258,500 | 500,234 | +93.5% | $8.6M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 648,275 | 250,561 | -61.3% | $4.3M | 2024-Q4 |
| NORGES BANK | NEW | — | 119,344 | — | $2.0M | 2024-Q4 |
| MORGAN STANLEY | ADD | 4,598,487 | 8,599,618 | +87.0% | $171.9M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 2,401,533 | — | $48.0M | 2024-Q3 |
9 unique insiders with 8 transactions. Net insider value: -$158.1K ($468.3K bought, $626.4K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 27, 2026 | Grossman Jerrold B | Director | BUY | 6,400 | $7.91 | $50.6K |
| May 12, 2026 | Grossman Jerrold B | Director | BUY | 12,500 | $8.01 | $100.1K |
| May 11, 2026 | Grossman Jerrold B | Director | BUY | 12,500 | $8.01 | $100.1K |
| Apr 1, 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | F | 20,362 | $9.11 | $185.5K |
| Mar 17, 2026 | Guiheen Lawrence P. | Director | G | 30,000 | $0.00 | $0.00 |
| Mar 16, 2026 | Grossman Adam S | President and CEO | M | 15,000 | $0.00 | $0.00 |
| Mar 16, 2026 | Grossman Adam S | President and CEO | SELL | 15,000 | $15.16 | $227.4K |
| Mar 16, 2026 | Grossman Adam S | President and CEO | M | 15,000 | $5.40 | $81.0K |
| Mar 13, 2026 | Guiheen Lawrence P. | Director | M | 30,000 | $0.00 | $0.00 |
| Mar 13, 2026 | Guiheen Lawrence P. | Director | M | 30,000 | $3.66 | $109.8K |
| Mar 9, 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | M | 2,500 | $0.00 | $0.00 |
| Mar 9, 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | SELL | 10,096 | $15.63 | $157.8K |
| Mar 9, 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | M | 2,500 | $5.00 | $12.5K |
| Mar 9, 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | J | 91,266 | $0.00 | $0.00 |
| Mar 7, 2026 | Grossman Adam S | President and CEO | F | 29,513 | $15.39 | $454.2K |
| Mar 7, 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | F | 4,235 | $15.39 | $65.2K |
| Mar 6, 2026 | ELMS STEVE | Director | BUY | 7,000 | $15.39 | $107.7K |
| Mar 6, 2026 | Grossman Adam S | President and CEO | F | 56,438 | $15.39 | $868.6K |
| Mar 6, 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | F | 10,059 | $15.39 | $154.8K |
| Mar 5, 2026 | ELMS STEVE | Director | BUY | 7,000 | $15.67 | $109.7K |
| Feb 26, 2026 | Grossman Adam S | President and CEO | F | 54,858 | $15.18 | $832.7K |
| Feb 19, 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | F | 8,161 | $16.32 | $133.2K |
| Feb 19, 2026 | Grossman Adam S | President and CEO | F | 24,793 | $16.32 | $404.6K |
| Feb 19, 2026 | Tade Brad L. | CFO and Treasurer | F | 6,479 | $16.32 | $105.7K |
| Feb 17, 2026 | Grossman Adam S | President and CEO | M | 15,000 | $5.40 | $81.0K |
| Feb 17, 2026 | Grossman Adam S | President and CEO | SELL | 15,000 | $16.08 | $241.2K |
| Feb 17, 2026 | Grossman Adam S | President and CEO | M | 15,000 | $0.00 | $0.00 |
| Feb 9, 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | A | 144,230 | $0.00 | $0.00 |
| Feb 9, 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | A | 91,631 | $0.00 | $0.00 |
| Feb 9, 2026 | Grossman Adam S | President and CEO | A | 444,711 | $0.00 | $0.00 |
| Feb 9, 2026 | Grossman Adam S | President and CEO | A | 282,529 | $0.00 | $0.00 |
| Feb 9, 2026 | KWON YOUNG | Director | A | 17,730 | $0.00 | $0.00 |
| Feb 9, 2026 | KWON YOUNG | Director | A | 10,690 | $0.00 | $0.00 |
| Feb 9, 2026 | FINGER ALISON CECILY | Director | A | 17,730 | $0.00 | $0.00 |
| Feb 9, 2026 | FINGER ALISON CECILY | Director | A | 10,690 | $0.00 | $0.00 |
| Feb 9, 2026 | Salas Eduardo Rene | Director | A | 17,730 | $0.00 | $0.00 |
| Feb 9, 2026 | Salas Eduardo Rene | Director | A | 10,690 | $0.00 | $0.00 |
| Feb 9, 2026 | Guiheen Lawrence P. | Director | A | 17,730 | $0.00 | $0.00 |
| Feb 9, 2026 | Guiheen Lawrence P. | Director | A | 10,690 | $0.00 | $0.00 |
| Feb 9, 2026 | ELMS STEVE | Director | A | 17,730 | $0.00 | $0.00 |
| Feb 9, 2026 | ELMS STEVE | Director | A | 10,690 | $0.00 | $0.00 |
| Feb 9, 2026 | Grossman Jerrold B | Director | A | 17,730 | $0.00 | $0.00 |
| Feb 9, 2026 | Grossman Jerrold B | Director | A | 10,690 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.3/10.
BULLISH
8-K
6/10
ADMA Biologics received FDA approval for label expansion of ASCENIV to include pediatric immune comp
May 4, 2026
NEUTRAL
DEFA14A
2/10
Analysis based on filing metadata only — document content was unavailable
Apr 15, 2026
BULLISH
8-K
8/10
ADMA Biologics reported record financial results for 2025 with 20% YoY revenue growth to $510 millio
Feb 25, 2026
Current analyst consensus: Strong Buy (80% buy). Based on 10 analysts: 2 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$16.75 mean target
+106.3% upside
Strong Buy (3.00)
$12.00 Low
$20.00 High
| Metric | Value |
|---|---|
| Current Price | $8.12 |
| Target Low | $12.00 |
| Target Mean | $16.75 |
| Target Median | $17.50 |
| Target High | $20.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.18 | $0.18 | $0.18 | 24.1% | -28.0% | 0↑ 1↓ | $0.1B | 10.2% | 2 |
| Next Q 2026-09-30 |
$0.21 | $0.21 | $0.21 | 32.1% | -25.0% | 0↑ 1↓ | $0.1B | 9.2% | 2 |
| Current FY 2026-12-31 |
$0.83 | $0.83 | $0.83 | 26.4% | -13.1% | 0↑ 1↓ | $0.6B | 11.7% | 1 |
| Next FY 2027-12-31 |
$1.06 | $1.02 | $1.10 | 27.3% | -14.8% | 0↑ 1↓ | $0.7B | 27.4% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.180 | |
| 7d ago | $0.230 | -0.050 |
| 30d ago | $0.250 | -0.070 |
| 60d ago | $0.250 | -0.070 |
| 90d ago | $0.230 | -0.050 |
3 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 7, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| May 7, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Apr 21, 2026 | Canaccord Genuity | INITIATE | — | Buy |
| Apr 13, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 26, 2026 | Cantor Fitzgerald | DOWNGRADE | Overweight | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| May 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| Apr 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
40°
Cool
Bearish
Neutral
Bullish
6 mentions
0 bullish
2 bearish
6 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 31, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| May 31, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 27, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 27, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
May 6, 2026
earnings_calendar
ADMA Q1 2026 Earnings Scheduled — 2026-05-06
May 5, 2026
earnings_calendar
ADMA Q1 2026 Earnings Scheduled — 2026-05-05
Apr 29, 2026
earnings
ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026
Conference Call Scheduled for May 6, 2026, at 4:30 p.m. ET <pre>Conference Call Scheduled for May 6, 2026, at 4:30 p.m. ET</pre>
Apr 21, 2026
short_volume
Short Volume: ADMA — 56.3% short (1.2M / 2.2M)
Short: 1,230,191 | Exempt: 15,875 | TRF Vol: 2,183,762 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
Mar 27, 2026
activist
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
<p align="center"><em>Short seller’s Characterization of ASCENIV’s Competitive Position Reflects Blatant Misunderstanding of ADMA’s Business and Its R
Mar 25, 2026
other
ADMA Biologics Addresses Misleading Short-Seller Report
<p align="justify">RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company
Mar 16, 2026
short_interest
FTD: ADMA — 36,705 shares ($0.6M) failed to deliver
Settlement: 20260316, Price: $15.15, FTD Value: $556,080.75, ADMA BIOLOGICS INC COM
Feb 25, 2026
earnings_calendar
ADMA Q4 2025 Earnings After Market Close — 2026-02-25